Rituximab injection is used alone or together with other medicines to treat a type of cancer called non-Hodgkin’s lymphoma (NHL). It is also used in combination with other Chemotherapy agents to treat mature B-cell non-Hodgkin’s lymphoma (NHL) and mature B-cell acute leukemia (B-ALL).
Apart from B-Cell malignancy it is also used to treat rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis and pemphigus vulgaris.
The original brand name for rituximab, a targeted cancer drug, is Rituxan, marketed by Roche in the United States. In other regions, it is sold under the brand name Mabthera. In India, this original molecule is marketed by Cipla as Ristova. Other brands in India are biosimilar rituximab, which are marketed at a lower price.
